Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non-Current Assets (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Other Non-Current Assets data on record, last reported at $87000.0 in Q1 2025.

  • For Q1 2025, Other Non-Current Assets changed 0.0% year-over-year to $87000.0; the TTM value through Mar 2025 reached $87000.0, changed 0.0%, while the annual FY2024 figure was $87000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $87000.0 in Q1 2025 per BTAI's latest filing, roughly flat from $87000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $965000.0 in Q1 2022 and bottomed at $87000.0 in Q2 2023.
  • Average Other Non-Current Assets over 4 years is $412384.6, with a median of $87000.0 recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: plummeted 90.59% in 2023, then changed 0.0% in 2024.
  • A 4-year view of Other Non-Current Assets shows it stood at $925000.0 in 2022, then tumbled by 90.59% to $87000.0 in 2023, then changed by 0.0% to $87000.0 in 2024, then changed by 0.0% to $87000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $87000.0 in Q1 2025, $87000.0 in Q4 2024, and $87000.0 in Q3 2024.